Dr. Barry Dworkin

Genentech asking FDA for accelerated approval for drug to treat early-stage HER-2 breast cancer

Madely Health Headlines Commentary for September 11, 2013

Source:

FDA backs accelerated approval for drug to treat early-stage breast cancer

CORRECTION: In the interview I state that the drug is not approved for use. It is indeed approved for the treatment of late-stage aggressive HER-2 breast cancer.

Related posts:

  1. Targeted chemotherapy for HER2 breast cancer patients shows good results in phase 3 study
  2. More information needed about woman's breast cancer before slamming Ontario Government for not covering breast-cancer drug
  3. Drug combo boosts advanced HER-2 breast cancer survival
  4. Breast cancer risk from hormone replacement needs perspective when compared to other contributing factors